PRGO

Perrigo Company plc (PRGO) - 2025 Annual Report Summary

Business Context and Reporting Period

This summary covers the Form 10-K for the fiscal year ended December 31, 2025. Perrigo is a leading pure-play self-care company operating primarily in North America and Europe. The company is organized into two reporting segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). In Q1 2026, the company began transitioning to a category-based segment reporting structure. The company is currently executing a "Three-S" strategy: Stabilizing store brand and infant formula businesses, Streamlining the global portfolio, and Strengthening key brands.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 2.8% to $4.25 billion, driven by lower sales in Digestive Health ($51.5M decrease) and Nutrition ($41.0M decrease, primarily infant formula), and the absence of a $15.0M Opill launch stocking benefit from the prior year. These were partially offset by favorable foreign currency translation ($49.8M increase).
• Significant Impairment Charges: The company recorded $1.36 billion in total impairment charges, primarily consisting of a $1.33 billion goodwill impairment ($917.1M in CSCA and $407.1M in CSCI). This was triggered by a sustained decrease in share price and lower expected cash flows related to infant formula market dynamics.
• Operating Loss: Operating income swung from a $112.9M profit in 2024 to a $1.12 billion loss in 2025, almost entirely due to the non-cash goodwill impairment charges.
• Divestitures: Completed the sale of the Richard Bittner Business in April 2025 for $14.4M, resulting in a $1.6M pre-tax loss. The Dermacosmetics Business is held for sale with an expected closing in Q1 2026.

Guidance, Outlook, and Risks

• Strategic Reviews: In November 2025, the company announced a strategic review of its infant formula business to accelerate cash flows and reassess a previously announced $240M investment. A similar review was initiated for the oral care business.
• Operational Enhancement: Launched a two-year enterprise-wide program targeting $80M-$100M in annual pre-tax cost savings, primarily through supply chain and distribution optimization, and a workforce reduction of approximately 7%.
• Future Impairment Risk: Due to the upcoming segment reorganization in Q1 2026, the company estimates potential additional structural non-cash goodwill impairment charges of up to $350 million in the first quarter of 2026.
• Tariff and Geopolitical Risks: The company faces uncertainty regarding U.S. tariffs on pharmaceuticals and ingredients, estimating a potential $30M-$40M increase in global cost of goods sold starting in 2026. Conflicts in Ukraine and the Middle East continue to pose supply chain risks.
• Regulatory Challenges: Ongoing FDA scrutiny of infant formula facilities (including a Form 483 issued in Feb 2026) has led to increased compliance costs and reduced production volumes. The company is also facing significant litigation regarding generic drug pricing (antitrust) and product liability (talc, ranitidine, acetaminophen).

Investor Verification Checklist

• Goodwill Impairment Sustainability: Verify the assumptions used in the fair value testing (discount rates, growth rates) and the likelihood of the estimated $350M additional impairment in Q1 2026.
• Infant Formula Turnaround: Assess the progress of the strategic review and the ability to regain market share amidst increased competition and regulatory costs (Operation Stork Speed).
• Liquidity and Debt Covenants: Confirm compliance with the 3.00x leverage ratio covenant given the significant operating loss and potential for further impairments.
• Legal Contingencies: Review the status of the generic drug pricing antitrust litigation (MDL No. 2724) and the potential for material settlements or judgments.
• Divestiture Execution: Monitor the closing of the Dermacosmetics Business sale and the realization of the $300M upfront payment.